Novartis said the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of Kisqali (ribociclib) in combination with an aromatase inhibitor for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative locally advanced or metastatic breast cancer as initial endocrine-based therapy.
A new model aims to change the standard of care around medical debt by addressing the financial toll of cancer using a multidisciplinary, tumor board model approach. Now, recent five-year data shows that it’s working.
